Summary of Game-Changing COVID-19 Nasal Vaccine Passes Initial Tests:
Researchers in Berlin have developed a live attenuated SARS-CoV-2 vaccine administered through the nose. According to a recent study, the vaccine confers better immunity than vaccines injected into a muscle. Two nasal vaccination formulations were already approved for use in India and China. These contain modified adenoviruses that are self-attenuating. Other live nasal vaccines are currently undergoing development and testing around the world. The next step is safety testing: The researchers collaborate with RocketVax AG, a Swiss start-up in Basel.
*****
Nasal COVID-19 vaccine development offers hope of protection against the virus.
Scientists have reported the successful development of a live attenuated vaccine for the nose that confers better immunity than vaccines injected into a muscle.
The spread of coronaviruses primarily occurs through the air when infected individuals expel droplets of saliva containing the virus through speaking, coughing, sneezing, or laughing. These airborne pathogens are then inhaled by others, leading to infection.
Live attenuated vaccines have been a key research focus in developing mucosal vaccines that can be delivered through the nasal route. Scientists at the Institute of Virologists at Freie Universität Berlin have done just that with new findings stating that the high concentration of antibodies well protects the live attenuated vaccine and can significantly reduce the virus’s transmissibility.
Studies showed that after two doses of the live attenuated vaccine, the virus could no longer replicate in the rodent model. The vaccine builds up immunity directly at the viral entry site and contains all virus components – not just the spike protein, as is the case with the mRNA vaccines.
The studies found that the best protection against SARS-CoV-2 was provided by double nasal vaccination, followed by a muscular injection of the mRNA vaccine and the subsequent nasal administration of the live attenuated vaccine.
While much more work needs to be done, these studies offer hope that developing and rolling nasal COVID-19 vaccines could be an effective and more convenient method of protecting against the virus.
Nasal vaccines: the way forward?
Nasal vaccines are a less invasive alternative to traditional injections for administering vaccines and are effective in providing immunity.
The advantage of nasal vaccines is that they offer a less invasive alternative to traditional injections and are effective in providing immunity. Additionally, because they do not require needles, they may be a good option for needle-phobic people or children who may be afraid of shots.
Scientists are looking at developing mucosal vaccines that can be delivered through the nasal route, referred to as “nasal vaccines.” Studies have shown that nasal vaccines confer better immunity than those injected into a muscle.
Nasal vaccines may also offer local immunity that can prevent an infection from setting in in the first place. Research indicates that live attenuated intranasal vaccines stimulate the formation of the antibody immunoglobulin A (IgA) directly on-site, thus preventing infection from occurring in the first place. IgA neutralizes pathogens by binding to them and preventing them from infecting respiratory tract cells while stimulating systemic immune responses that provide overall protection from infection.
The best protection against the SARS-CoV-2 was provided by double nasal vaccination, followed by a muscular injection of the mRNA vaccine and the subsequent nasal administration of the live attenuated vaccine, according to recent research.
Although more work needs to be done, these nasal vaccines offer hope that the development and rollout of nasal COVID-19 vaccines could be an effective and more convenient method of protecting against the virus.
Comments are closed